The application to expand the gastric cancer indication for the immuno-oncology drug Keytruda (pembrolizumab, MSD) has been given a ‘redliberation’ decision. The drug is currently seeking reimbursement for 17 indications, but financial issues have prevented a conclusion.

The Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee held its 9th meeting for 2024 on the 18th and deliberated on the proposed reimbursement standards for anticancer drugs.

Keytruda’s result was the center of attention. MSD, the maker of Keytruda, has applied for reimbursement expansion for 17 indications. The CDDC had deliberated Keytruda’s agenda 4 times but deferred the deci